Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Libivirumab, an antibody targeting Hepatitis B Virus Surface Antigen.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Exbivirumab, an antibody targeting Hepatitis B Surface Antigen.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zalutumumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Volociximab, an antibody targeting ITGA5B1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tucotuzumab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tadocizumab, an antibody targeting ITGA2B and ITGB3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Iratumumab, an antibody targeting CD30.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bapineuzumab, an antibody targeting Amyloid-beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Veltuzumab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anrukinzumab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alacizumab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Robatumumab, an antibody targeting IGF-1R.